Finding 480851 (2021-003)

Material Weakness Repeat Finding
Requirement
P
Questioned Costs
-
Year
2021
Accepted
2024-08-09

AI Summary

  • Core Issue: Year-end schedules for federal grants were not reconciled, leading to overdrawn accounts and inaccurate financial statements.
  • Impacted Requirements: Non-compliance with 2 CFR 200.508 and 2 CFR 200.510 regarding proper financial management and reporting of federal awards.
  • Recommended Follow-up: Ensure schedules are prepared and reviewed by supervisors; train staff for accurate entries and reconciliations, with completion expected by May 1, 2024.

Finding Text

Finding 2021-003: Reconciliation of Accounts Material Weakness Federal Programs: Research and Development Cluster: 47.076 Criteria or Specific Requirement (Including Statutory, Regulatory, or Other Citation): According to 2 CFR 200.508 "Auditee Responsibilities" the auditee must prepare appropriate financial statements, including the SEFA (as specifically defined under 2 CFR 200.510 "Financial statements"). Title 2 CFR 200.510 "financial statements" requires recipients of Federal funds to prepare a SEFA for the period covered by the auditee's financial statements, which must include the total Federal awards expended. In addition, as noted in 2 CFR 200.302 "Financial management", the financial management system of each non-Federal entity must provide for identification, in its accounts, of all Federal awards received and expended and the Federal programs under which they were received, and records that identify adequately the source and application of funds for federally-funded activities including expenditures. Condition: The year-end schedules for federal grants receivable, and for net assets, and for vacation payable were not reconciled and needed to be revised and updated. Cause: Errors in transferring balances between years occurred, which impacted carry-over amounts and the ending balances as of 12/31/2021. Related to vacation payables, the schedule had not been properly adjusted to account for the number of days in the last pay period. Effect or Potential Effect: Three federal grant accounts were overdrawn as of 12/31/2021, creating a liability to the federal government. The related grant receivable and liability balances were not properly stated before adjustment as a result. Questioned Costs: $80,978. Identification as a Repeat Finding, if Applicable: 2020-003 Recommendation: We recommend AAPT staff prepare schedules used to prepare entries into the accounting information system or which the information in the schedules will otherwise be used to initiate financial transactions, and the transactions and schedules be reviewed by a supervisor. Views of Responsible Officials and Planned Corrective Actions: The outstanding liability due to NSF of $80,978 will be reimbursed when AAPT files the next drawn down request. Anticipated date of drawn down will be by July 31,2024. The senior accountant will be trained to prepare entries previously prepared by the CFO The senior accountant will reconcile accounts, and provide updated current schedules. The CFO will review and approve the entries and schedules prepared by the Senior accountant. Anticipated Completion Date: 05/01/2024 Responsible Official: Michael Brosnan, CFO

Categories

Material Weakness Reporting Matching / Level of Effort / Earmarking

Other Findings in this Audit

  • 480849 2021-003
    Material Weakness Repeat
  • 480850 2021-005
    Significant Deficiency Repeat
  • 480852 2021-005
    Significant Deficiency Repeat
  • 480853 2021-003
    Material Weakness Repeat
  • 480854 2021-005
    Significant Deficiency Repeat
  • 480855 2021-003
    Material Weakness Repeat
  • 480856 2021-004
    Significant Deficiency Repeat
  • 480857 2021-005
    Significant Deficiency Repeat
  • 480858 2021-003
    Material Weakness Repeat
  • 480859 2021-005
    Significant Deficiency Repeat
  • 480860 2021-006
    Significant Deficiency Repeat
  • 480861 2021-003
    Material Weakness Repeat
  • 480862 2021-005
    Significant Deficiency Repeat
  • 480863 2021-003
    Material Weakness Repeat
  • 480864 2021-004
    Significant Deficiency Repeat
  • 480865 2021-005
    Significant Deficiency Repeat
  • 480866 2021-003
    Material Weakness Repeat
  • 480867 2021-005
    Significant Deficiency Repeat
  • 480868 2021-003
    Material Weakness Repeat
  • 480869 2021-005
    Significant Deficiency Repeat
  • 480870 2021-003
    Material Weakness Repeat
  • 480871 2021-005
    Significant Deficiency Repeat
  • 480872 2021-003
    Material Weakness Repeat
  • 480873 2021-005
    Significant Deficiency Repeat
  • 480874 2021-003
    Material Weakness Repeat
  • 480875 2021-005
    Significant Deficiency Repeat
  • 480876 2021-003
    Material Weakness Repeat
  • 480877 2021-005
    Significant Deficiency Repeat
  • 480878 2021-005
    Significant Deficiency Repeat
  • 480879 2021-005
    Significant Deficiency Repeat
  • 480880 2021-003
    Material Weakness Repeat
  • 480881 2021-005
    Significant Deficiency Repeat
  • 480882 2021-005
    Significant Deficiency Repeat
  • 1057291 2021-003
    Material Weakness Repeat
  • 1057292 2021-005
    Significant Deficiency Repeat
  • 1057293 2021-003
    Material Weakness Repeat
  • 1057294 2021-005
    Significant Deficiency Repeat
  • 1057295 2021-003
    Material Weakness Repeat
  • 1057296 2021-005
    Significant Deficiency Repeat
  • 1057297 2021-003
    Material Weakness Repeat
  • 1057298 2021-004
    Significant Deficiency Repeat
  • 1057299 2021-005
    Significant Deficiency Repeat
  • 1057300 2021-003
    Material Weakness Repeat
  • 1057301 2021-005
    Significant Deficiency Repeat
  • 1057302 2021-006
    Significant Deficiency Repeat
  • 1057303 2021-003
    Material Weakness Repeat
  • 1057304 2021-005
    Significant Deficiency Repeat
  • 1057305 2021-003
    Material Weakness Repeat
  • 1057306 2021-004
    Significant Deficiency Repeat
  • 1057307 2021-005
    Significant Deficiency Repeat
  • 1057308 2021-003
    Material Weakness Repeat
  • 1057309 2021-005
    Significant Deficiency Repeat
  • 1057310 2021-003
    Material Weakness Repeat
  • 1057311 2021-005
    Significant Deficiency Repeat
  • 1057312 2021-003
    Material Weakness Repeat
  • 1057313 2021-005
    Significant Deficiency Repeat
  • 1057314 2021-003
    Material Weakness Repeat
  • 1057315 2021-005
    Significant Deficiency Repeat
  • 1057316 2021-003
    Material Weakness Repeat
  • 1057317 2021-005
    Significant Deficiency Repeat
  • 1057318 2021-003
    Material Weakness Repeat
  • 1057319 2021-005
    Significant Deficiency Repeat
  • 1057320 2021-005
    Significant Deficiency Repeat
  • 1057321 2021-005
    Significant Deficiency Repeat
  • 1057322 2021-003
    Material Weakness Repeat
  • 1057323 2021-005
    Significant Deficiency Repeat
  • 1057324 2021-005
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
43.001 Science $41,592
47.049 Mathematical and Physical Sciences $23,501
47.076 Education and Human Resources $20,896